Biomarker Based Individual Risk Assessment for Prostate Cancer
Abstract
The goal of this work is to develop a biomarker profile of prostate cancer risk, based on cell signaling proteins that serve as high-level biomarkers of cellular subsystems; e.g., tissue transglutaminase (TTGase), cadherins or catenins, and gelsolin, G-actin or thymosin-beta. TTGase, cadherins, and G-actin are strong biomarkers of prostate cancer and may be strong biomarkers of field disease and premalignancy. The biomarker profile will identity individuals for prostate cancer prevention and rebiopsy, with high sensitivity and specificity, complementing serum PSA screening that captures 95% of prostate cancer cases with only 20% specificity. Protein biomarkers are quantified in single cells by Quantitative Fluorescence Imaging Analysis (QFlA), which requires stoichiometric labeling of high-quality tissue specimens. A complex and highly integrated configuration of standard operating procedures, tissue culture models, and optimal tissue specimens has been developed and recent implementation supports down regulation of TTGase as a biomarker for prostate premalignancy. Fluorescence signals are currently generated with organic fluorophores but we are now investigating inorganic nanocrystals for biomarker labeling and expect, during the next year of this award, to apply nanocrystal-antibody conjugates to analysis of multiplexed signals from single cells as part of our development of an extensive QFlA data set with prostate specimens.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2003
- Accession Number
- ADA420787
Entities
People
- George P. Hemstreet Iii
Organizations
- University of Nebraska Medical Center